AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04782323
Drug: aQII-6 Investigational
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Trial: NCT04782323
Drug: aQII-9 Investigational
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Trial: NCT04782323
Drug: aQII-10 Investigational
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Trial: NCT04782323
Drug: aQII-11 Investigational
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Trial: NCT04709536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Trial: NCT00239317
Drug: Tamusulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04617028
Drug: Placebo to match Hydroxycarbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Hydroxycarbamide Tablets administered orally twice daily
Trial: NCT06365580
Drug: Kylo-0603 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated orally.
Trial: NCT06365580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated orally.
Trial: NCT06264440
Drug: BIIB122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05684965
Drug: XTX301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XTX301 monotherapy
Trial: NCT06463548
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
Trial: NCT05851508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanal injection with saline, natriumchloride 0.9%
Trial: NCT05393817
Drug: caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
Trial: NCT05143762
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive placebo 10 ml normal saline IV.
Trial: NCT06554470
Drug: Systemic Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
Trial: NCT06554470
Drug: Local Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
Trial: NCT04896489
Drug: Hydrocortisone 20 MG
RxNorm normalized name: hydrocortisone 20 MG
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants receive Hydrocortisone 20 MG
Trial: NCT05818735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
Trial: NCT05415150
Drug: Thrombolytic Agent
RxNorm normalized name: Thrombolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may receive one or more of the treatment options
Trial: NCT05802810
Drug: [14C]JT001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
Trial: NCT05787418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 8 times per day for 7 consecutive days
Trial: NCT05369052
Drug: contezolid acefosamil (IV)/contezolid (PO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Trial: NCT05542355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Trial: NCT05062239
Drug: Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuance of prior statin therapy
Trial: NCT05062239
Drug: No-intervention.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuance of prior statin therapy
Trial: NCT04452461
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
Trial: NCT06577532
Drug: ABO2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
Trial: NCT06223828
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/kg/dose (max dose 500mg) once daily for 3 days
Trial: NCT04818346
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB054707 will be administered once daily
Trial: NCT04818346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or INCB054707 will be administered once daily
Trial: NCT06393881
Drug: UIC202201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take UIC202201 once a day for 7 days
Trial: NCT05380934
Drug: TQH3821 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
Trial: NCT05380934
Drug: TQH3821 tablets (Placebo)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
Trial: NCT05380934
Drug: Methotrexate tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
Trial: NCT05713318
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
Trial: NCT05713318
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
Trial: NCT06171113
Drug: GSK4024484C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses administrated orally with 240 mL of water.
Trial: NCT06171113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses administrated orally with 240 mL of water.
Trial: NCT04952545
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04952545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT06170372
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Trial: NCT05497284
Drug: LTP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTP001 will be administered once daily in the morning
Trial: NCT05497284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to LTP001 will be administered once daily in the morning
Trial: NCT05497284
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nintedanib, pirfenidone, or neither
Trial: NCT04788108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05116540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT03972124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft-gel capsules containing placebo
Trial: NCT06433180
Drug: Administration of the sham (PLACEBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
Trial: NCT06300008
Drug: cetylated fatty acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Trial: NCT06300008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Trial: NCT00093678
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03762395
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
Trial: NCT04589819
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be a sugar solution of the manufacturer's design.
Trial: NCT06553066
Drug: Deep neuromascular blockage
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)
Trial: NCT06553066
Drug: Moderate neuromascular blockage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
Trial: NCT06555237
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopiramide and Beta blockers orally
Trial: NCT05127421
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied twice a day (BID) to affected areas
Trial: NCT06394518
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo for TNP-2092 active drug
Trial: NCT04274166
Drug: secukinumab 150 mg (2 injections per dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 150 mg (2 injections per dose
Trial: NCT05403541
Drug: Matching Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05084196
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 5 mg capsule by mouth at bedtime
Trial: NCT04626791
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04626791
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05388903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05388903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06316362
Drug: SMOF lipid 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
Trial: NCT04647526
Drug: [Lu-177]-PNT2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
Trial: NCT04633057
Drug: NordiFlex
RxNorm normalized name: Norditropin Nordiflex Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
Trial: NCT06256783
Drug: Baozhu Keli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once enrolled, participants will be administrated Baozhu Keli
Trial: NCT04755712
Drug: Rachianesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
Trial: NCT05429177
Drug: QY101 ointment or vehicle
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QY101 ointment or vehicl topical applied to skin
Trial: NCT05542576
Drug: AMDX2011P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMDX2011P single bolus injection intravenous for diagnostic review
Trial: NCT05051865
Drug: SHR1020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab combined with SHR1020 for advanced melanoma
Trial: NCT05823012
Drug: levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium 10 mg/mL
Trial: NCT03745664
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
Trial: NCT05568888
Drug: BE1116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-Factor Prothrombin Complex administered by intravenous (IV) infusion
Trial: NCT05568888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT06067412
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy in fits
Trial: NCT06669390
Drug: NG11-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution.
Trial: NCT06670898
Drug: [14C] NS-580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT05445011
Drug: Fludarabine + Cyclophosphamide + TAA05 Cell Injection
RxNorm normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
Trial: NCT05501860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Sterile Topical Ophthalmic Solution
Trial: NCT05449613
Drug: acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
Trial: NCT04389580
Drug: Drug: Isotretinoin plus Tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen
Trial: NCT04389580
Drug: Aerosolized Isotretinoin plus Tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen
Trial: NCT06128590
Drug: Mepivacaine hydrochloride in combination with epinephrine
RxNorm normalized name: epinephrine / mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure.
Trial: NCT05611359
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT04997174
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in ERAS group received celecoxib
Trial: NCT05876065
Drug: XC
RxNorm normalized name: Excof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
Trial: NCT04831736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Trial: NCT05498259
Drug: CHOP-like Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
Trial: NCT05020639
Drug: TQB3820 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3820 is a novel cereblon-modulating agent.
Trial: NCT04916470
Drug: Placebo (Semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
Trial: NCT06580574
Drug: PD1/PDL1 antibody monotherapy, up to 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-specific, according to Drug Instructions
Trial: NCT05800392
Drug: DEC103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is composed by two medications: An active sublingual pill and an active oral one.
Trial: NCT05800392
Drug: Placebo DEC103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
Trial: NCT05846516
Drug: ATP150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05846516
Drug: ATP152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05120934
Drug: Placebo 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg tablet with no active study ingredient for 4 weeks
Trial: NCT05120934
Drug: Placebo 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg tablet with no active study ingredient for 4 weeks
Trial: NCT05160558
Drug: BIIB132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT06180824
Drug: Gelafundin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
Trial: NCT05234684
Drug: Placebo + R-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Trial: NCT05528120
Drug: VC004 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration after fasting/high-fat meal
Trial: NCT05528120
Drug: VC004 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration after high-fat/fasting meal
Trial: NCT06173778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active medication, self-administered